Sofinnova Partners
162+Portfolio
We invest in early‑stage European life‑science companies developing breakthrough biopharma and med‑tech therapies, as well as sustainable industrial biotech innovations. Our hands‑on approach supports founders from seed through later‑stage to bring transformative health solutions to patients.
Where they invest
Geography
Portfolio footprintHover a country to explore
- United States of America
- 20.8%
- France
- 18.8%
- United Kingdom
- 14.6%
- Germany
- 6.3%
- Italy
- 6.3%
- Other
- 14.7%
Darker countries represent a larger share of the portfolio.
What they back
Industries
- Biotechnology
- 56.3%
- Artificial Intelligence
- 35.4%
- Healthcare Technology
- 18.8%
- Data & Analytics
- 16.7%
- Enterprise Software
- 14.6%
- Digital Health
- 12.5%
% of all portfolio companies. Industry categories can overlap.
Stages
Stage indicator
Seed → Series C+
Fund details
Funds
Sofinnova Capital VI
Vintage 2008 • $286M
Sofinnova Capital VII
Vintage 2012 • $264M
Sofinnova Capital VIII
Vintage 2015 • $330M
Sofinnova Capital IX
Vintage 2018 • $366.3M
Sofinnova Capital X
Vintage 2021 • $519.2M
Sofinnova Capital XI
Vintage 2025 • $715M